



CINACALCET REMAINS EFFECTIVE IN PRIMARY HYPERPARATHYROIDISM AFTER 4 YEARS OF TREATMENT

I. Luque Fernández, F. del Val Zaballos, A. Luque Pazos, A. Vicente Delgado, J. Sastre Marcos, A. Marco Martínez
 Department of Endocrinology and Nutrition - Hospital Virgen de la Salud, Toledo (Spain)

INTRODUCTION

Cinacalcet is an oral calcimimetic indicated in treatment of primary hyperparathyroidism in patients who are unable to undergo parathyroidectomy: do not accept surgery, there is failure of previous surgery or serious comorbidity that makes surgery impossible.

METHODS




Descriptive study that includes 9 patients with primary hyperparathyroidism who have completed at least 48 months of treatment with cinacalcet (7 patients refusal to parathyroidectomy and 2 surgery not possible due to comorbidities). We recorded clinical and biochemical data at baseline and after 3, 6, 12, 24 and 48 months of treatment.

RESULTS

Results of Ca, P and PTH at baseline, and at 12 and 48 months of treatment

Table 1: Basal characteristics

Age at diagnosis (Years)	76 ±6,4
Females	88,9 %
Time of treatment (months)	49



No further variation was observed after 24 and 48 months compared to 12 months follow up except for an increase in PTH to baseline levels.

Normocalcemia (Ca < 10.2 mg/dl) was achieved in 55.7% patients

Usually the medication was well-tolerated and no serious adverse events were observed

CONCLUSION

Hypercalcemia is rapidly improved by Cinacalcet and remains stable after 48 months follow-up. Cinacalcet is an effective and safe alternative in non-surgical treatment of primary hyperparathyroidism in case of surgical contraindications.